Pharm

Terazosin

search

Terazosin, Hytrin

  • See Also
  1. Postsynaptic Alpha Adrenergic Antagonist
  • Indications
  1. Hypertension
    1. Not first-line Antihypertensives, and avoid using as monotherapy (higher risk of CVA and CHF)
  2. Benign Prostatic Hypertrophy
    1. Selective Alpha-1a Antagonists (e.g. Tamsulosin) are preferred
  3. Medical Expulsive Therapy for Ureteral Stone
    1. Replaced by the preferred Selective Alpha-1a Antagonists (e.g. Tamsulosin)
  • Dosing
  1. Hypertension
    1. Start 1 mg orally at bedtime
    2. Titrate to effective dose 1 to 5 mg daily or in divided doses
    3. Maximum 20 mg/day
  2. Benign Prostatic Hypertrophy (replaced by Selective Alpha-1a Antagonists)
    1. Start 1 mg orally at bedtime
    2. Titrate to effect by doubling dose every 1-2 weeks (to 2, 5 and 10 mg)
    3. Observe for effects after 4 to 6 weeks on optimal dose (typically 10 mg)
    4. Maximum of 20 mg/day
  • Safety
  1. Pregnancy Category C
  2. Unknown safety in Lactation
  • Mechanism
  1. See Alpha Adrenergic Receptor (Alpha-1 Antagonist)
  2. Peripheral Alpha-1 Adrenergic Antagonist
    1. Arterial and Venous Vasodilation
  • Adverse Effects
  1. See Postsynaptic Alpha Adrenergic Antagonist
  • Resources
  1. Terazosin (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43e92495-2cf2-46dd-a80c-f0c3c88c7b73
  • References
  1. (2020) Med Lett Drugs Ther 62(1598): 73-80
  2. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 62-3
  3. Hamilton (2020) Tarascon Pocket Pharmacopoeia